Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture by Rossi, Leonardo et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Methodology
Detection of human MCP-4/CCL13 isoforms by SELDI 
immunoaffinity capture
Leonardo Rossi*1, Ramy Moharram2, Brian M Martin2, Richard L White3 and 
Monica C Panelli4
Address: 1Department of Human Morphology and Applied Biology, University of Pisa, 56126 Pisa, Italy, 2National Institute of Mental Health 
NIMH, National Institutes of Health, Bethesda, Maryland 20892 USA, 3Carolinas Medical Center, Blumenthal Cancer Center, Charlotte, North 
Carolina, 28232 USA and 4Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 
Bethesda, Maryland 20892, USA
Email: Leonardo Rossi* - leoros@biomed.unipi.it; Ramy Moharram - moharrar@mail.nih.gov; Brian M Martin - BrianMartin@mail.nih.gov; 
Richard L White - Richard.White@carolinashealthcare.org; Monica C Panelli - mpanelli@mail.cc.nih.gov
* Corresponding author    
Abstract
Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) is a member of a distinct, structurally-
related subclass of CC chemokines mainly involved in recruitment of eosinphils to inflammatory
sites. Recent evidence demonstrates that serum level of this protein strongly increases following
high dose IL-2 immunotherapy. The physiological form of human MCP-4/CCL13 has yet to be
purified. Therefore, the primary structure of the biologically relevant (mature) form has not been
established. By using SELDI immunoaffinity capture technology we describe two mature isoforms
both present in serum before and after high-dose IL-2 immunotherapy.
Introduction
Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) is
member of a distinct, structurally-related subclass of CC
chemokines. MCP-4/CCL13 is a major chemoattractants
for eosinophils, basophils monocytes and T lymphocytes.
The MCP protein family bind to specific G-protein-cou-
pled receptors, initiating a signal cascade within the cell
[1,2]. Expression of MCP-4/CCL13 mRNA and protein is
greater in the sputum, epithelium, submucosal inflamma-
tory cells and bronchoalveolar lavage fluid of asthmatics
than in healthy individuals [3,4]. Involvement of MCPs
has also been demonstrated in renal inflammation and
atopic dermatitis [5,6] and the expression of this protein
is also correlated with enhanced inflammatory immune
responses during immunotherapy. Specifically, massive
production of chemoattractants, has been demonstrated
by quantitative methods (multiplex protein array/Search-
light) in renal cell carcinoma (RCC) patient serum after
high dose IL-2 therapy [7].
Our qualitative analysis of MCP-4/CCL13 was based on
SELDI immunocapture. We and others have previously
used this proteomic tool to rapidly screen and differenti-
ate, based on mass/charge (m/z) ratios isoforms of serum
proteins [8,9]. This type of approach represents an integral
step in the detection of biologically relevant differences
among systemic proteins during physiological and patho-
logical states. It also aids in the biomarker discovery proc-
ess associated with a disease state or the occurrence of a
vigorous immune response such as that elicited by high
dose IL-2. SELDI spectra may in fact suggest the presence
of specific post-translational modifications such as glyco-
sylation or phosphorylation at specific sites, early protein
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truncation and other events [10] that may define a specific
isoform and thus constitute a biomarker.
The aim of this study was to qualitatively characterize
MCP-4/CCL13 by Surface Enhanced Laser Desorption
Ionization Time Of Flight Mass Spectrometry (SELDI-
TOF-MS™) in the serum of RCC patients undergoing high
dose IL-2 immunotherapy. We were also able to detect, for
the first time in human serum two systemic MCP-4/
CCL13 isoforms of similar molecular weight before and
after IL-2 treatment.
Materials and methods
Patients and serum collection
Ten patients with metastatic RCC were recruited at the
Carolinas Medical Center (Charlotte, NC) to receive sys-
temic high-dose (720,000 IU/Kg every 8 hrs) IL-2 admin-
istration (Proleukin, Chiron, Emeryville, CA). Serum was
collected prior to IL-2 treatment (PRE) and 3 hours after
the fourth (POST 4) dose a time point that corresponds to
the clinical observation of its peak effects (three to four
hours after administration of intravenous bolus IL-2)
[7,8], aliquoted and stored at -80°C until testing. All
tested aliquots were subjected to only one freeze-thaw
cycle.
Immunoprecipitation
Five hundred micrograms of MCP-4/CCL13 antibody
clone 18 (Santa Cruz Biotechnology Santa Cruz, CA) were
bound to ImmunoPure Immobilized Protein G column
according to the manufacturer protocol (Seize X Protein G
Immunoprecipitation Kit, Pierce, Rockford, IL) for 1 hour
at room temperature. The bound antibody was
crosslinked to protein G using disuccinimidyl suberate
(DSS) reagent. After quenching the reaction (washing
multiple times with ImmunoPure® IgG elution buffer pH
2.8 containing primary amine), beads were equilibrated
in the column with binding/washing buffer (0.14 M
NaCl, 0.008 M sodium phosphate, 0.002 M potassium
phosphate and 0.01 M KCl, pH7.4. One milliliter of
serum was diluted 1:1 with binding/washing buffer and
incubated with the resin containing the immobilized anti-
body on a roller platform for five hours at room tempera-
ture. Twenty microliters of halt protease inhibitor
cocktail, EDTA free (Pierce) were added to inhibit pro-
teases and prevent protein degradation.
Unbound proteins were removed by centrifugation and a
fraction of the flow-through was saved for further analy-
sis.
Proteins bound to the column were eluted with 200 µl of
elution buffer and neutralized by adding 10 µl of 1 M tris-
HCl. The eluted proteins were stored at -80°C for future
analysis.
ProteinChip immunoaffinity capture
Immunoaffinity capture was performed using a PG20
Array (ProteinChip® antibody capture kit, Ciphergen Bio-
systems, Fremont, CA, USA). Polyclonal anti-MCP-4/
CCL13 antibody clone 18 and clone 20 (Santa Cruz Bio-
technology Santa Cruz, CA), and Polyclonal anti IL-6 anti-
body (Abcam, Cambridge, MA) were used at a final
concentration of 0.2 µg/µl in PBS. These affinity purified
goat polyclonal antibodies were raised against a peptide
mapping near the carboxy terminus of MCP-4 of human
origin. Protein G arrays were placed in a bioprocessor
(Ciphergen Biosystems) and rehydrated in PBS for 1 min
before antibody binding to protein G. The capture of
MCP-4/CCL13 protein was performed by placing 20 µl of
the appropriate antibody on a single spot of the array fol-
lowed by incubation for 90 min at room temperature on
a shaker. Unbound antibodies were removed by washing
twice with 400 µl of wash buffer (0.5% (v/v) Triton X100
in PBS) and twice with PBS. Bound antibodies were cross-
linked to protein G by adding 30 µl of bis(sulfosuccinim-
idyl) suberate (supplied in the ProteinChip antibody cap-
ture kit) at a final concentration of 0.5 mg/ml for 30 min
at room temperature. The residual active sites were finally
deactivated by adding 30 µl of 0.5 M ethanolamine in PBS
pH 8. After a 15 min incubation each spot was washed
twice with 400 ul of wash buffer and twice with PBS.
Twenty µl of samples diluted 1:1 with PBS were subse-
quently placed on the spots. Chips were incubated for 3
hours at room temperature, washed twice with 400 ul of
wash buffer and twice with PBS, rinsed in 1 M HEPES
buffer and air dried. Prior to SELDI-TOF MS analysis, 0.6
µl of saturated sinapinic acid (SPA) solution was added to
each spot.
Surface Enhanced Laser Desorption/Ionization – Time of 
Flight Mass Spectroscopy (SELDI-TOF MS)
All mass spectra were recorded in the positive-ion mode
on the SELDI mass spectrometer PBS IIc ProteinChip
Array reader, a linear laser desorption/ionization time-of-
flight mass spectrometer with time-lag focusing [14]. Raw
data were analyzed using computer software provided by
the manufacturer and are reported as average masses.
Results
Identification of MCP-4/CCL13 isoforms in sera from RCC 
patient undergoing high dose IL-2 treatment
The use of SELDI-TOF-MS combined with specific anti-
bodies raised against MCP-4/CCL13 protein allowed us to
identify a dominant peak at about 8945 m/z and a second
peak at about 9113 m/z that approximately matched with
MCP-4/CCL13 putative molecular weight calculated from
the amino acid sequence. These peaks were especially
prominent when straight serum obtained after the 4th
dose of IL-2 was applied on PG20 chip pre-coated with
anti MCP-4/CCL13 clone 18 antibody (Fig 1A-C: spectraJournal of Translational Medicine 2006, 4:5 http://www.translational-medicine.com/content/4/1/5
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SELDI immunoaffinity capture of MCP-4/CCL13 from patient sera after high dose IL-2 immunotherapy Figure 1
SELDI immunoaffinity capture of MCP-4/CCL13 from patient sera after high dose IL-2 immunotherapy. Anti MCP-4/CCL13 
clone 18 (A-I, O), anti MCP-4/CCL13 clone 20 (Q,R) and anti IL-6 (L-N) polyclonal antibody were immobilized on a protein G 
array. Spectra from 6000 to 10000 Da are depicted for each experiment. No significant peaks were detected out of this range. 
Immunoaffinity capture spectra of patient 2(A), 3(B), 5(C) serum diluted 1:1 in PBS. Immunoaffinity capture spectra of MCP-4/
CCL13 immunoprecipitated from patient 2(D), 3(E), 5(F). (G) Immunoaffinity capture spectra of the un-bound fraction (flow-
through) obtained during the immunoprecipitation procedure of patient 2(G), 3(H), 5(I). Immunoaffinity capture spectra of 
MCP-4/CCL13 immunoprecipitated from patient 2(L), 3(M), 5(N) serum on IL-6 pre-coated chip. (O) Immunoaffinity capture 
spectra of PBS. (P) spectra of patient 2 serum applied on an uncoupled PG20 chip. Immunoaffinity capture spectra of MCP-4/
CCL13 immunoprecipitated from patient 2(Q) and 3(R) serum on MCP-4/CCL13 clone 20 pre-coated chip. Intensity scale for 
A and P spectra = 0 – 10. Intensity scale for Q and R = 0 – 2. Red bar = MCP-4/CCL13 clone 18 pre-coated chip; orange bar = 
MCP-4/CCL13 clone 20 pre-coated chip; blue bar = IL-6 pre-coated chip; dotted bar = Uncoupled PG20 chip.
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from 3 representative patients P2, P3 and P5). We immu-
noprecipitated MCP-4/CCL13 prior to immunocapture
on the chip surface in order to establish the specificity of
the detection as well as reduce the background from con-
taminating proteins. One ml of serum was immunopre-
cipitated with anti MCP-4/CCL13 clone 18 antibody and
the eluted proteins were applied on PG20 chips pre-
coated with the same antibody. A peak at about 8945 m/
z accompanied by a smaller peak at about 9113 m/z was
detected in all the samples (Fig 1D-F: spectra from patient
P2, P3 and P5). The unbound fraction (flow-through, see
materials and methods for details) obtained during the
immunoprecipitation procedure did not show any spe-
cific binding when applied on MCP-4/CCL13 clone 18
pre-coated PG20 chips (Fig 1G-I: spectra from patient P2,
P3 and P5) confirming the specificity of our detection. No
peaks were obtained when the immunoprecipitated frac-
tion was applied on PG20 chips pre-coated with the unre-
lated anti IL-6 antibody (Fig 1L-N: spectra from patient
P2, P3 and P5). No peaks were detected in chips loaded
with negative controls (PBS applied on MCP-4/CCL13
pre-coated chips Fig 1O, or crude serum applied on PG20
chip without pre-coating, Fig 1P). To further confirm the
specificity of detection of MCP-4/CCL13, the immuno-
precipitated fraction was applied to PG20 chips pre-
coated with a different clone of anti MCP-4/CCL13 anti-
body (clone 20) The aforementioned 8945 peak was also
detected by this antibody clone (Fig 1Q,R: spectra from
patient P2, P3) in the pre and post samples. SELDI immu-
nocapture technology allowed us to detect MCP-4/CCL13
protein in serum samples obtained prior to IL-2 treat-
ment; no differences in the expression level between pre
and post samples were detectable using this technology in
our experimental condition (data not shown).
Discussion
Novel mass spectrometry based technologies, such as
SELDI-TOF-MS, have shown promising results especially
when combined with biospecific interactive surfaces. The
use of specific antibodies applied on the SELDI chip sur-
face is a powerful tool to selectively identify a desired tar-
get in a complex protein mixture. Accurate information
about the molecular weight, discrimination between iso-
forms and possible capture of co-precipitating proteins,
represent some of the most attractive information that
could be obtained by using this technology.
MCP-4/CCL13 is a chemokine whose concentration in
the blood is in the range of 200–300 pg/ml [3,7]. This
protein is generally easily detected and quantified by
ELISA but not by Western Blot analysis [11]. Matrix
assisted laser desorption mass spectrometry (MALDI)
analysis of purified recombinant human MCP-4/CCL13
expressed in insect revealed a predominant peak with a
mass of about 8575 m/z, which starts with residue 24at
QPDAL. Two minor peaks at about 8760 and 9314 m/z,
starting at residue 22 and 17 respectively were also
detected. The alignment of MCP-4/CCL13 sequence with
those of well characterized members of the CC-chemok-
ine family strongly suggested that the recombinant form
of m/z 8575, synthesized by Drosophila cells, is the correct
mature protein [11,12]. Alternative splicing has not been
found [13]. To date, human MCP-4/CCL13 has not yet
been purified from serum or other human fluid/tissue and
no evidence of naturally occurring "isoforms" have been
reported. By using SELDI immunoaffinity capture chip
technology we were able to identify two MCP-4/CCL13
isoforms and evaluate their molecular weight in a com-
plex protein mixture such as serum. The molecular
weights of the isoforms we detected in the serum do not
correspond to those previously described for the recom-
binant protein. We detected a major peak at m/z of 8945
instead of 8575, and a minor peak of a m/z of 9113
instead of 8760. The apparent molecular weight of the
major serum component is consistent with a peptide start-
ing at residue 20 and extending to residue 98 of the amino
acid sequence deduced from cDNA. Thus it would appear
possible that the signal peptide is 19 amino acids and not
the 16 previously postulated from the recombinant forms
(UniProtKB/SWISS-Pro-entry-Q996126) [15]. Three pos-
sible phosphorylation sites (S 44, S 50, T 55) are found in
the MCP-4/CCL13 sequence when analyzed by NetPhos
2.0 Server (EXPASY database http://au.expasy.org/), these
are the only post translational modifications potentially
occurring given the MCP-4/CCL13 amino acid sequence.
It is possible that some of the differences between the iso-
forms we detected and those observed in the recombinant
protein are the result of phosphorylation. We cannot
exclude post-translational modification of the serum
MCP-4/CCL13 nor speculate on the identity of our 9113
M/Z component. Our assessment of MCP-4/CCL13 iso-
forms by SELDI immunocapture was purely qualitative
(differential quantification between pre and post treat-
ment samples was not consistent). We postulated that in
our experimental condition, saturation of antibody
crosslinked to the MCP-4/CCL13 protein on the SELDI
chip was the limiting factor as previously described by
Hess et al. [10]. In conclusion, this short report establishes
for the first time the occurrence of two different isoforms
of human MCP-4/CCL13 in the peripheral blood. Fur-
thermore, it demonstrates the versatility of SELDI in rap-
idly detecting MCP-4/CCL13 isoforms.
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